LeMaitre Vascular Inc. (NASDAQ:LMAT) has been given an average rating of “Buy” by the nine ratings firms that are currently covering the company. One analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $19.61.
Several research analysts recently issued reports on LMAT shares. Canaccord Genuity reaffirmed a “buy” rating and set a $21.00 target price on shares of LeMaitre Vascular in a research report on Tuesday, September 6th. Brean Capital upped their target price on LeMaitre Vascular from $17.50 to $20.00 and gave the company a “buy” rating in a research report on Thursday, July 28th. Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th. Sidoti lowered LeMaitre Vascular from a “buy” rating to a “neutral” rating and set a $23.00 price objective on the stock. in a report on Thursday, September 22nd. Finally, Barrington Research increased their price objective on LeMaitre Vascular from $18.50 to $20.00 and gave the company an “outperform” rating in a report on Thursday, July 28th.
LeMaitre Vascular (NASDAQ:LMAT) opened at 19.84 on Tuesday. LeMaitre Vascular has a 12-month low of $11.96 and a 12-month high of $22.50. The company has a 50-day moving average price of $19.27 and a 200-day moving average price of $16.19. The stock has a market capitalization of $366.33 million, a PE ratio of 39.84 and a beta of 0.51.
LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, July 27th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.03. LeMaitre Vascular had a return on equity of 11.90% and a net margin of 11.43%. The company had revenue of $22.40 million for the quarter, compared to analyst estimates of $21.59 million. The firm’s quarterly revenue was up 12.6% compared to the same quarter last year. Analysts expect that LeMaitre Vascular will post $0.55 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Monday, August 22nd were issued a dividend of $0.045 per share. This represents a $0.18 annualized dividend and a yield of 0.91%. The ex-dividend date was Thursday, August 18th. LeMaitre Vascular’s dividend payout ratio (DPR) is 36.73%.
In related news, insider David B. Roberts sold 6,452 shares of the firm’s stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $21.05, for a total transaction of $135,814.60. Following the sale, the insider now directly owns 69,793 shares of the company’s stock, valued at $1,469,142.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Peter R. Gebauer sold 30,000 shares of the firm’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $16.47, for a total value of $494,100.00. Following the sale, the insider now directly owns 25,374 shares in the company, valued at $417,909.78. The disclosure for this sale can be found here. Corporate insiders own 28.90% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC raised its stake in LeMaitre Vascular by 44.4% in the first quarter. Acadian Asset Management LLC now owns 184,245 shares of the company’s stock valued at $2,860,000 after buying an additional 56,631 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of LeMaitre Vascular by 18.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 216,813 shares of the company’s stock worth $3,365,000 after buying an additional 33,754 shares in the last quarter. Acrospire Investment Management LLC acquired a new position in shares of LeMaitre Vascular during the first quarter worth about $265,000. State Street Corp increased its position in shares of LeMaitre Vascular by 4.3% in the first quarter. State Street Corp now owns 297,877 shares of the company’s stock worth $4,623,000 after buying an additional 12,189 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of LeMaitre Vascular by 7.0% in the first quarter. Geode Capital Management LLC now owns 113,650 shares of the company’s stock worth $1,763,000 after buying an additional 7,421 shares in the last quarter. 59.88% of the stock is currently owned by hedge funds and other institutional investors.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.